Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.64 -2.7%	$3.10	$2.46 ▼ $4.15	$320.07M	0.25	324,012 shs	424,024 shs
ENGN enGene	$3.81 +0.3%	$3.61	$2.65 ▼ $11.00	$194.20M	-0.42	127,734 shs	73,984 shs
ESPR Esperion Therapeutics	$1.11 -5.1%	$0.99	$0.69 ▼ $3.94	$231.89M	0.7	4.80 million shs	2.92 million shs
INCR InterCure	$1.50 -3.8%	$1.53	$1.17 ▼ $2.62	$71.09M	1.18	25,971 shs	76,959 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-0.82%	+1.11%	+14.47%	+37.36%	+12.00%
ENGN enGene	-1.80%	+4.67%	+0.79%	-7.52%	-58.36%
ESPR Esperion Therapeutics	-5.21%	+12.76%	-9.02%	+4.72%	-54.69%
INCR InterCure	+1.01%	+2.04%	0.00%	+13.64%	-34.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.3282 of 5 stars	3.3	2.0	0.0	0.0	0.6	2.5	1.3
ENGN enGene	2.7748 of 5 stars	3.5	3.0	0.0	0.0	1.5	2.5	0.6
ESPR Esperion Therapeutics	4.1964 of 5 stars	3.4	3.0	0.0	3.9	2.6	1.7	0.6
INCR InterCure	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	64.84% Upside
ENGN enGene	3.00	Buy	$23.29	511.17% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	530.63% Upside
INCR InterCure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INCR, ENGN, AVIR, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
ESPR Esperion Therapeutics	$332.31M	0.66	$0.02 per share	48.70	($1.97) per share	-0.56
INCR InterCure	$238.85M	0.29	N/A	N/A	$2.36 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.65	N/A	N/A	N/A	N/A	-31.26%	-29.27%	8/6/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	N/A
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest INCR, ENGN, AVIR, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.94	19.94
ENGN enGene	0.09	12.66	12.66
ESPR Esperion Therapeutics	N/A	1.18	0.81
INCR InterCure	0.34	1.73	1.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
ENGN enGene	64.16%
ESPR Esperion Therapeutics	47.39%
INCR InterCure	8.34%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
ENGN enGene	10.40%
ESPR Esperion Therapeutics	1.70%
INCR InterCure	0.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	70.09 million	Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
INCR InterCure	350	45.57 million	N/A	Optionable

INCR, ENGN, AVIR, and ESPR Headlines

Recent News About These Companies

Intercure 3 Warrants (INCR_t3) - Investing.com

June 28, 2025 | investing.com

Intercure 3 Warrants (INCR_t3) - Investing.com UK

June 28, 2025 | uk.investing.com

Short Interest in InterCure Ltd. (NASDAQ:INCR) Increases By 26.9%

June 18, 2025 | marketbeat.com

InterCure Reports Strong Start to 2025 Amid Recovery Efforts

May 1, 2025 | tipranks.com

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

May 1, 2025 | prnewswire.com

InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak

February 14, 2025 | markets.businessinsider.com

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

February 12, 2025 | prnewswire.com

InterCure Secures Major Funding to Boost Growth

December 22, 2024 | markets.businessinsider.com

Cannabis co InterCure raising NIS 66m for Nir Oz facility

December 22, 2024 | en.globes.co.ilE

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

December 20, 2024 | prnewswire.com

Rising High: Exclusive talk with house of brands Carma HoldCo

November 7, 2024 | markets.businessinsider.com

InterCure Ltd. (INCR)

October 16, 2024 | finance.yahoo.com

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

September 14, 2024 | benzinga.com

InterCure partners with Cookies to launch cannabis pharmacies in Germany

August 30, 2024 | investing.com

Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany

August 30, 2024 | msn.com

InterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

August 30, 2024 | finanznachrichten.de

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

August 29, 2024 | globenewswire.com

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

August 28, 2024 | finance.yahoo.com

Electreon Wireless Ltd (ELWS)

July 31, 2024 | investing.com

Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ

May 24, 2024 | markets.businessinsider.com

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

May 22, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
New Catalysts to Drive NVIDIA’s Stock Price Even Higher
By Thomas Hughes | June 16, 2025
View New Catalysts to Drive NVIDIA’s Stock Price Even Higher
Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
By Thomas Hughes | June 18, 2025
View Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
By Leo Miller | June 10, 2025
View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway

INCR, ENGN, AVIR, and ESPR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.64 -0.10 (-2.67%)

As of 07/7/2025 04:00 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

enGene NASDAQ:ENGN

$3.81 +0.01 (+0.26%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$3.79 -0.02 (-0.52%)

As of 07/7/2025 06:19 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Esperion Therapeutics NASDAQ:ESPR

$1.11 -0.06 (-5.13%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 07/7/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

InterCure NASDAQ:INCR

$1.50 -0.06 (-3.85%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$1.52 +0.02 (+1.33%)

As of 07/7/2025 07:20 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time